SHANGHAI — To further deepen its presence in the global pharmaceutical market and expand its strategic partnership network, Newland Pharma has announced its upcoming participation in the 24th CPhI China & 19th PMEC China (CPHI & PMEC China 2026). Embracing an open and collaborative mindset, Newland Pharma aims to work alongside global industry peers to explore emerging opportunities in the pharmaceutical landscape. The company extends a cordial invitation to long-standing clients, prospective partners, and industry stakeholders worldwide to visit its booth for face-to-face discussions, fostering strategic insights and mutual growth.

A Premier Industry Gathering: Connecting Key Global Markets

Originating in Europe with a legacy spanning over three decades, CPHI is a premier global mega-event for the pharmaceutical industry. Today, the CPHI portfolio spans Europe, China, South Korea, India, Japan, Southeast Asia, the Middle East, and North America. Through its multi-dimensional platform of exhibitions, conferences, and digital networking, it connects over 100,000 pharmaceutical professionals globally, unlocking commercial potential and driving international market expansion.

As a bellwether for the pharmaceutical sector in Asia and beyond, CPHI & PMEC China has develop over 20 years to driving industry evolution. The event's scale and influence continue to expand, covering critical vertical segments such as APIs, excipients, CRO/CMO services, biopharmaceuticals, packaging, drug delivery systems, and laboratory equipment. It serves as a highly integrated trading and knowledge-sharing platform, enabling pharmaceutical enterprises to optimize supply chain layouts and accelerate innovative transformations.

Technical Rigor & Quality: Fortifying Core Industrial Strength

Newland Pharma is a high-tech pharmaceutical enterprise integrating R&D, manufacturing, sales, and service, with a long-standing focus on specialty APIs and high-end pharmaceutical intermediates. Adhering to an integrated development strategy of "Intermediates—APIs—Finished Dosage Forms," the company has established a comprehensive business model spanning the entire industry value chain.

Relying on the core advantages of chiral drug preparation technology and continuous flow catalytic hydrogenation research platform, the products cover  core medical fields such as anti-infection, diabetes, local anesthesia, cardiovascular and so on. With stable quality and strict quality control, it has been widely recognized in the global market.

Newland Pharma maintains deep academic collaborations with elite institutions, including Tsinghua University and China Pharmaceutical University. Utilizing modern production facilities and intelligent digital management systems, Newland Pharma strictly adheres to international quality standards such as GMP, FDA, and CEP, supported by an end-to-end traceability framework.

In recent years, several of the company’s proprietary formulations have secured regulatory approval and passed the consistency evaluations, alongside the commercialization of numerous invention patents. Driven by mature manufacturing technologies, economies of scale, and a resilient supply chain, Newland Pharma’s products are exported worldwide, backed by extensive international operational experience and premium partnership networks.

Going Global: Embarking on a New Chapter of Internationalization

Internationalization remains central to Newland Pharma's strategic vision. The company is continuously optimizing its global marketing and support networks to steadily advance its overseas footprint. Focus on key layouts in Latin America, Southeast Asia, Europe, the Middle East and other regions, where Newland Pharma aligns its product and service architecture with localized market demands. The company is actively advancing US DMF filings and European CEP certification declaration for for multiple product lines, strengthening the global brand equity of Chinese pharmaceutical enterprises.

In terms of international collaboration, Newland Pharma champions an open, win-win philosophy. The company actively engages in technical exchanges and joint R&D with global pharmaceutical peers and research institutes to continuously iterate its products and manufacturing processes. Concurrently, by offering flexible collaboration models across supply chains, distribution channels, and project development, Newland Pharma is dedicated to building a resilient, mutually beneficial global pharmaceutical ecosystem.

Join Us: Partnering for a New Era of Growth

At CPHI China 2026, Newland Pharma will showcase its core competitive products and innovative technical solutions, demonstrating its comprehensive full-chain capabilities. The company will feature a dedicated one-on-one consultation area at its booth to provide tailored partnership strategies. Global buyers, stakeholders, and industry peers are sincerely invited to visit, explore collaborative synergies, and co-author the future of the pharmaceutical industry.

Exhibition Information

• Event Name: The 24th CPHI China & 19th PMEC China (CPHI & PMEC China 2026)

• Venue: Shanghai New International Expo Centre (SNIEC)

• Date: June 16 - June 18, 2026

• Newland Pharma Booth No.: W4B76